TY  - BOOK
AU  - Benjamin Gesundheit
AU  - Joshua P. Rosenzweig
AB  - The ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.
DO  - 10.3389/978-2-88945-358-0
ID  - OAPEN ID: 25658
KW  - theranostic nanomedicine
KW  - cancer immunotherapy
KW  - oncolytic viruses
KW  - antitumor immunity
KW  - oncoimmunology
KW  - gene expression
KW  - transgenes
L1  - https://www.frontiersin.org/research-topics/5352/oncolytic-viruses---genetically-engineering-the-future-of-cancer-therapy
LA  - English
LK  - https://directory.doabooks.org/handle/20.500.12854/55224
PB  - Frontiers Media SA
PY  - 2017
SN  - 9782889453580
TI  - Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapynull
ER  - 
